Fig. 2

Kaplan–Meier curves for overall survival (OS) of subgroups (pretreated patients with metastatic cutaneous melanoma). Subgroups were stratified as follows: by a the absence of brain metastases before the first dose of ipilimumab; Absence of brain metastases: median OS 12.3 months (95 % CI 6.0–19.4); brain metastases present: median OS 4.2 months (95 % CI 2.0–6.1); b the number of ipilimumab doses (4 versus <4); 4 doses: median OS 13.5 months (95 % CI 7.9–20.4); <4 doses: median OS 2.1 months (95 % CI 1.6–4.1); and c the absolute lymphocyte count (ALC) (≥1000/µl versus <1000/µl) before the second dose (i.e. week 4) of ipilimumab; ALC ≥1000/µl: median OS 9.9 months (95 % CI 6.1–18.5); ALC <1000/µl: median OS 3.6 months (95 % CI 1.8–5.6)